<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885363</url>
  </required_header>
  <id_info>
    <org_study_id>2011-20</org_study_id>
    <secondary_id>2011-A00987-34</secondary_id>
    <nct_id>NCT02885363</nct_id>
  </id_info>
  <brief_title>Prognosis of Isolated Left Ventricular Non-compaction in Adults</brief_title>
  <acronym>NCVG</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to clarify prospectively prognosis of patients newly&#xD;
      diagnosed as carriers of a LVNC (incident cases) (i.e. without the occurrence of a survival&#xD;
      of the following events: death, heart transplantation or hospitalization for cardiovascular&#xD;
      complications). In a second time, prognosis factors will be identify in these patients with&#xD;
      LVNC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Isolated Left Ventricular Non Compaction (LVNC) is a rare cause of cardiomyopathy supposed to&#xD;
      result from the cessation of normal embryogenesis infarction, and characterized by persistent&#xD;
      ventricular trabeculations prominent.&#xD;
&#xD;
      This is frequently a familial disease, but for which genetic characterization is still&#xD;
      incomplete, and then requires the identification of new genes is desirable.&#xD;
&#xD;
      The prognosis of LVNC is uncertain, with a mortality rate reported in the literature ranging&#xD;
      from 2 to 38%. Some series conclude that LVNC is a very severe heart disease, responsible for&#xD;
      a high mortality, other that LVNC is frequently associated with a favorable prognosis. These&#xD;
      series are however limited by the short duration of follow-up and the small number of&#xD;
      patients included.&#xD;
&#xD;
      Between 2004 and 2006, a French registry LVNC, included 105 cases. It was found out that the&#xD;
      LVNC was associated with a high rate of complications such as outbreaks of severe heart&#xD;
      failure, need for heart transplantation, severe rhythm disorders, and embolic events. The&#xD;
      prognosis of LVNC in France appears as pejorative:&#xD;
&#xD;
        1. - there is no evidence that prognosis is different from other forms of cardiomyopathies.&#xD;
&#xD;
        2. - the results of this register can be skewed by the inclusion of incident and prevalent&#xD;
           cases (statistical survival bias).&#xD;
&#xD;
      Thus, a longer-term monitoring and the identification of relevant prognostic markers are&#xD;
      imperative to better understand this rare disease and to improve the therapeutic management.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of death of cardiac origin</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of a cardiac transplantation</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of hospitalization due to cardiac event</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Left Ventricular Non Compaction</condition>
  <arm_group>
    <arm_group_label>Patients with newly diagnosed Left Ventricular Non Compaction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient newly diagnosed with Left Ventricular Non Compaction (diagnose &lt; 6 months), confirmed by echocardiography associated or not with MRI, after centralized review</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Idiopathic Dilated Cardiomyopathy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient newly diagnosed with Idiopathic Dilated Cardiomyopathy (diagnose &lt; 6 months), confirmed by echocardiography associated or not with MRI, after centralized review</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical examination</intervention_name>
    <arm_group_label>Patients with Idiopathic Dilated Cardiomyopathy</arm_group_label>
    <arm_group_label>Patients with newly diagnosed Left Ventricular Non Compaction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <arm_group_label>Patients with Idiopathic Dilated Cardiomyopathy</arm_group_label>
    <arm_group_label>Patients with newly diagnosed Left Ventricular Non Compaction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <arm_group_label>Patients with Idiopathic Dilated Cardiomyopathy</arm_group_label>
    <arm_group_label>Patients with newly diagnosed Left Ventricular Non Compaction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged over 18 years&#xD;
&#xD;
          -  Presenting with Left Ventricular Non Compaction (LVNC, Group 1) or Idiopathic Dilated&#xD;
             Cardiomyopathy (DCM, Group 2)&#xD;
&#xD;
          -  At distance of an acute heart failure thrust (&gt; 1 month)&#xD;
&#xD;
          -  Newly diagnosed (less than 6 months)&#xD;
&#xD;
          -  Diagnosis confirmed by echocardiography associated or not with a Magnetic Resonance&#xD;
             Imaging (MRI) confirmed after central review&#xD;
&#xD;
          -  Having signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Patients who were diagnosed more than 6 months ago (prevalent cases)&#xD;
&#xD;
          -  Presence of an associated cardiac disease, including valvular, ischemic, or congenital&#xD;
             disease&#xD;
&#xD;
          -  Refusal to sign the informed consent form&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine GEINDRE</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilbert HABIB, Pr</last_name>
    <phone>04 91 38 75 87</phone>
    <phone_ext>+33</phone_ext>
    <email>gilbert.habib@free.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie CHARVIN</last_name>
    <phone>04 91 38 17 05</phone>
    <phone_ext>+33</phone_ext>
    <email>nathalie.charvin@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert HABIB</last_name>
      <phone>04 91 38 75 87</phone>
      <email>gilbert.habib@free.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>August 30, 2016</last_update_submitted>
  <last_update_submitted_qc>August 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

